Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06945406 | A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes | PHASE1 | RECRUITING | 124 | — | — | May 16, 2025 | Dec 1, 2026 | Mar 11, 2026 | 1 | Germany |
A summary of SAEs and AEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4057996 Part A (Cohorts A1-A5) | EXPERIMENTAL | LY4057996 administered subcutaneously (SC) and/or intravenously (IV) |
| Placebo Part A (Cohort A1-A5) | PLACEBO_COMPARATOR | Placebo administered SC and/or IV |
| LY4057996 Part B | EXPERIMENTAL | LY4057996 administered SC |
| LY4057996 Part C | EXPERIMENTAL | LY4057996 and interventions of pre-study basal insulin and Lispro administered SC |
| Degludec Part A (Cohort A2-A5) | ACTIVE_COMPARATOR | Degludec administered SC and/or IV |
| Degludec Part B | ACTIVE_COMPARATOR | Degludec administered SC |
| Name | Type | Description |
|---|---|---|
| LY4057996 SC | DRUG | Administered SC |
| LY4057996 IV | DRUG | Administered IV |
| Placebo SC | DRUG | Administered SC |
| Placebo IV | DRUG | Administered IV |
| Degludec SC | DRUG | Administered SC |
| Lispro SC | DRUG | Administered SC |
| Degludec IV | DRUG | Administered IV |
| Pre-study basal insulin SC | DRUG | Administered SC |
Inclusion Criteria: Part A for Healthy Participants: * Are overtly healthy as determined by medical evaluation, including medical history, physical exam, laboratory tests, and cardiac screening assessment Part A for Type 2 Diabetes (T2DM) Participants: * Are participants with T2DM diagnosed grea...